IL6ST and autoimmune disease: Data from molecular structural studies, cell assays and in vivo models indicate that targeting the IL-6:gp130 axis by blockade of Site3 on IL-6 represents a favorable point of pharmaceutical intervention in autoimmune disease, and strongly support the ongoing clinical evaluation of olokizumab.